Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides.

LaFleur DW, Abramyan D, Kanakaraj P, Smith RG, Shah RR, Wang G, Yao XT, Kankanala S, Boyd E, Zaritskaya L, Nam V, Puffer BA, Buasen P, Kaithamana S, Burnette AF, Krishnamurthy R, Patel D, Roschke VV, Kiener PA, Hilbert DM, Barbas CF 3rd.

MAbs. 2013 Mar-Apr;5(2):208-18. doi: 10.4161/mabs.23043.

2.

Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis.

Kanakaraj P, Puffer BA, Yao XT, Kankanala S, Boyd E, Shah RR, Wang G, Patel D, Krishnamurthy R, Kaithamana S, Smith RG, LaFleur DW, Barbas CF 3rd, Hilbert DM, Kiener PA, Roschke VV.

MAbs. 2012 Sep-Oct;4(5):600-13. doi: 10.4161/mabs.21227. Epub 2012 Aug 6.

3.

Targeting the junction of CɛmX and ɛ-migis for the specific depletion of mIgE-expressing B cells.

Chowdhury PS, Chen Y, Yang C, Cook KE, Nyborg AC, Ettinger R, Herbst R, Kiener PA, Wu H.

Mol Immunol. 2012 Oct;52(3-4):279-88. doi: 10.1016/j.molimm.2012.06.004. Epub 2012 Jun 29. Erratum in: Mol Immunol. 2013 Jan;53(1-2):172.

PMID:
22750228
4.

Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis.

Greenberg SA, Higgs BW, Morehouse C, Walsh RJ, Kong SW, Brohawn P, Zhu W, Amato A, Salajegheh M, White B, Kiener PA, Jallal B, Yao Y.

Genes Immun. 2012 Apr;13(3):207-13. doi: 10.1038/gene.2011.61. Epub 2011 Sep 1.

PMID:
21881594
5.

Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway.

Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, Brohawn P, Kiener PA, Richman L, Fiorentino D, Greenberg SA, Jallal B, Yao Y.

Ann Rheum Dis. 2011 Nov;70(11):2029-36. doi: 10.1136/ard.2011.150326. Epub 2011 Jul 28.

PMID:
21803750
6.

IL-9 governs allergen-induced mast cell numbers in the lung and chronic remodeling of the airways.

Kearley J, Erjefalt JS, Andersson C, Benjamin E, Jones CP, Robichaud A, Pegorier S, Brewah Y, Burwell TJ, Bjermer L, Kiener PA, Kolbeck R, Lloyd CM, Coyle AJ, Humbles AA.

Am J Respir Crit Care Med. 2011 Apr 1;183(7):865-75. doi: 10.1164/rccm.200909-1462OC. Epub 2010 Oct 22.

7.

Respiratory syncytial virus (RSV) RNA loads in peripheral blood correlates with disease severity in mice.

Torres JP, Gomez AM, Khokhar S, Bhoj VG, Tagliabue C, Chang ML, Kiener PA, Revell PA, Ramilo O, Mejias A.

Respir Res. 2010 Sep 15;11:125. doi: 10.1186/1465-9921-11-125.

8.

MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function.

Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, Reed JL, Woods R, Dall'acqua WW, Stephens GL, Erjefalt JS, Bjermer L, Humbles AA, Gossage D, Wu H, Kiener PA, Spitalny GL, Mackay CR, Molfino NA, Coyle AJ.

J Allergy Clin Immunol. 2010 Jun;125(6):1344-1353.e2. doi: 10.1016/j.jaci.2010.04.004.

PMID:
20513525
9.

Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma.

Busse WW, Katial R, Gossage D, Sari S, Wang B, Kolbeck R, Coyle AJ, Koike M, Spitalny GL, Kiener PA, Geba GP, Molfino NA.

J Allergy Clin Immunol. 2010 Jun;125(6):1237-1244.e2. doi: 10.1016/j.jaci.2010.04.005.

PMID:
20513521
10.

Cell type-specific recognition of human metapneumoviruses (HMPVs) by retinoic acid-inducible gene I (RIG-I) and TLR7 and viral interference of RIG-I ligand recognition by HMPV-B1 phosphoprotein.

Goutagny N, Jiang Z, Tian J, Parroche P, Schickli J, Monks BG, Ulbrandt N, Ji H, Kiener PA, Coyle AJ, Fitzgerald KA.

J Immunol. 2010 Feb 1;184(3):1168-79. doi: 10.4049/jimmunol.0902750. Epub 2009 Dec 30.

11.

The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators.

Dimasi N, Gao C, Fleming R, Woods RM, Yao XT, Shirinian L, Kiener PA, Wu H.

J Mol Biol. 2009 Oct 30;393(3):672-92. doi: 10.1016/j.jmb.2009.08.032. Epub 2009 Aug 20.

PMID:
19699208
12.

Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.

Bruckheimer EM, Fazenbaker CA, Gallagher S, Mulgrew K, Fuhrmann S, Coffman KT, Walsh W, Ready S, Cook K, Damschroder M, Kinch M, Kiener PA, Woods R, Gao C, Dall'Acqua W, Wu H, Coats S.

Neoplasia. 2009 Jun;11(6):509-17, 2 p following 517.

13.

Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus.

Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, Brohawn P, Zhang J, White B, Coyle AJ, Kiener PA, Jallal B.

Arthritis Rheum. 2009 Jun;60(6):1785-96. doi: 10.1002/art.24557.

14.

Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.

Lutterbuese R, Raum T, Kischel R, Lutterbuese P, Schlereth B, Schaller E, Mangold S, Rau D, Meier P, Kiener PA, Mulgrew K, Oberst MD, Hammond SA, Baeuerle PA, Kufer P.

J Immunother. 2009 May;32(4):341-52. doi: 10.1097/CJI.0b013e31819b7c70.

PMID:
19342971
15.

Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus.

Yao Y, Higgs BW, Morehouse C, de Los Reyes M, Trigona W, Brohawn P, White W, Zhang J, White B, Coyle AJ, Kiener PA, Jallal B.

Hum Genomics Proteomics. 2009 Nov 17;2009. pii: 374312. doi: 10.4061/2009/374312.

16.

A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo.

Jackson D, Gooya J, Mao S, Kinneer K, Xu L, Camara M, Fazenbaker C, Fleming R, Swamynathan S, Meyer D, Senter PD, Gao C, Wu H, Kinch M, Coats S, Kiener PA, Tice DA.

Cancer Res. 2008 Nov 15;68(22):9367-74. doi: 10.1158/0008-5472.CAN-08-1933.

17.

Identification of antibody neutralization epitopes on the fusion protein of human metapneumovirus.

Ulbrandt ND, Ji H, Patel NK, Barnes AS, Wilson S, Kiener PA, Suzich J, McCarthy MP.

J Gen Virol. 2008 Dec;89(Pt 12):3113-8. doi: 10.1099/vir.0.2008/005199-0.

18.

Macrophage impairment underlies airway occlusion in primary respiratory syncytial virus bronchiolitis.

Reed JL, Brewah YA, Delaney T, Welliver T, Burwell T, Benjamin E, Kuta E, Kozhich A, McKinney L, Suzich J, Kiener PA, Avendano L, Velozo L, Humbles A, Welliver RC Sr, Coyle AJ.

J Infect Dis. 2008 Dec 15;198(12):1783-93. doi: 10.1086/593173.

PMID:
18980502
19.

YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages.

Létuvé S, Kozhich A, Arouche N, Grandsaigne M, Reed J, Dombret MC, Kiener PA, Aubier M, Coyle AJ, Pretolani M.

J Immunol. 2008 Oct 1;181(7):5167-73.

20.

Type I interferon: potential therapeutic target for psoriasis?

Yao Y, Richman L, Morehouse C, de los Reyes M, Higgs BW, Boutrin A, White B, Coyle A, Krueger J, Kiener PA, Jallal B.

PLoS One. 2008 Jul 16;3(7):e2737. doi: 10.1371/journal.pone.0002737. Erratum in: PLoS ONE. 2009;4(3). doi: 10.1371/annotation/fbcbcab9-2e87-4ec7-af6e-c6e9e64ad4b3.

21.

Genomic-based high throughput screening identifies small molecules that differentially inhibit the antiviral and immunomodulatory effects of IFN-alpha.

Chen B, Zong Q, Cibotti R, Morris C, Castaneda J, Naiman B, Liu D, Glodek A, Sims GP, Herbst R, Horrigan SK, Kiener PA, Soppet D, Coyle AJ, Audoly L.

Mol Med. 2008 Jul-Aug;14(7-8):374-82. doi: 10.2119/2008-00028.Chen.

22.

Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab.

Wu H, Pfarr DS, Losonsky GA, Kiener PA.

Curr Top Microbiol Immunol. 2008;317:103-23. Review.

PMID:
17990791
23.

Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis.

Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, Beggs AH, Amato AA, Greenberg SA.

Arthritis Rheum. 2007 Nov;56(11):3784-92.

24.
25.

Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.

Hammond SA, Lutterbuese R, Roff S, Lutterbuese P, Schlereth B, Bruckheimer E, Kinch MS, Coats S, Baeuerle PA, Kufer P, Kiener PA.

Cancer Res. 2007 Apr 15;67(8):3927-35.

26.

Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE.

Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, Hua J, An LL, Audoly L, La Rosa G, Bierhaus A, Naworth P, Marshak-Rothstein A, Crow MK, Fitzgerald KA, Latz E, Kiener PA, Coyle AJ.

Nat Immunol. 2007 May;8(5):487-96. Epub 2007 Apr 8. Erratum in: Nat Immunol. 2007 Jul;8(7):780.

PMID:
17417641
27.

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.

Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA.

J Mol Biol. 2007 May 4;368(3):652-65. Epub 2007 Feb 20.

PMID:
17362988
28.

Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin.

Mulgrew K, Kinneer K, Yao XT, Ward BK, Damschroder MM, Walsh B, Mao SY, Gao C, Kiener PA, Coats S, Kinch MS, Tice DA.

Mol Cancer Ther. 2006 Dec;5(12):3122-9.

29.

Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo.

Ulbrandt ND, Ji H, Patel NK, Riggs JM, Brewah YA, Ready S, Donacki NE, Folliot K, Barnes AS, Senthil K, Wilson S, Chen M, Clarke L, MacPhail M, Li J, Woods RM, Coelingh K, Reed JL, McCarthy MP, Pfarr DS, Osterhaus AD, Fouchier RA, Kiener PA, Suzich JA.

J Virol. 2006 Aug;80(16):7799-806.

30.

Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.

Hentschel N, Krusch M, Kiener PA, Kolb HJ, Salih HR, Schmetzer HM.

Eur J Haematol. 2006 Aug;77(2):91-101. Epub 2006 Jun 23.

PMID:
16800841
31.

Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).

Dall'Acqua WF, Kiener PA, Wu H.

J Biol Chem. 2006 Aug 18;281(33):23514-24. Epub 2006 Jun 21.

32.

Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency.

Mejías A, Chávez-Bueno S, Ríos AM, Aten MF, Raynor B, Peromingo E, Soni P, Olsen KD, Kiener PA, Gómez AM, Jafri HS, Ramilo O.

Antimicrob Agents Chemother. 2005 Nov;49(11):4700-7.

33.

Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization.

Wu H, Pfarr DS, Tang Y, An LL, Patel NK, Watkins JD, Huse WD, Kiener PA, Young JF.

J Mol Biol. 2005 Jul 1;350(1):126-44.

PMID:
15907931
34.

Analysis of human and primate CD2 molecules by protein sequence and epitope mapping with anti-human CD2 antibodies.

Damschroder MM, Kozhich AA, Woods RM, Cheng L, Mullikin BA, Wilson SD, Ulbrandt ND, Bachy CM, Wu H, Suzich JA, Kiener PA, Dall'Acqua WF, White WI.

Mol Immunol. 2004 Aug;41(10):985-1000.

PMID:
15302161
35.

EphA2 expression is associated with aggressive features in ovarian carcinoma.

Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA, Sood AK.

Clin Cancer Res. 2004 Aug 1;10(15):5145-50.

36.

Identification of purine inhibitors of phosphodiesterase 7 (PDE7).

Pitts WJ, Vaccaro W, Huynh T, Leftheris K, Roberge JY, Barbosa J, Guo J, Brown B, Watson A, Donaldson K, Starling GC, Kiener PA, Poss MA, Dodd JH, Barrish JC.

Bioorg Med Chem Lett. 2004 Jun 7;14(11):2955-8.

PMID:
15125967
37.

Serum levels of CD137 ligand and CD178 are prognostic factors for progression of myelodysplastic syndrome.

Salih HR, Nuessler V, Denzlinger C, Starling GC, Kiener PA, Schmetzer HM.

Leuk Lymphoma. 2004 Feb;45(2):301-8.

PMID:
15101715
38.
39.

PC cell-derived growth factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma.

Pan CX, Kinch MS, Kiener PA, Langermann S, Serrero G, Sun L, Corvera J, Sweeney CJ, Li L, Zhang S, Baldridge LA, Jones TD, Koch MO, Ulbright TM, Eble JN, Cheng L.

Clin Cancer Res. 2004 Feb 15;10(4):1333-7.

40.

Differential EphA2 epitope display on normal versus malignant cells.

Coffman KT, Hu M, Carles-Kinch K, Tice D, Donacki N, Munyon K, Kifle G, Woods R, Langermann S, Kiener PA, Kinch MS.

Cancer Res. 2003 Nov 15;63(22):7907-12.

41.

Fas (CD95) induces proinflammatory cytokine responses by human monocytes and monocyte-derived macrophages.

Park DR, Thomsen AR, Frevert CW, Pham U, Skerrett SJ, Kiener PA, Liles WC.

J Immunol. 2003 Jun 15;170(12):6209-16.

42.

Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties.

Wrobleski ST, Chen P, Hynes J Jr, Lin S, Norris DJ, Pandit CR, Spergel S, Wu H, Tokarski JS, Chen X, Gillooly KM, Kiener PA, McIntyre KW, Patil-Koota V, Shuster DJ, Turk LA, Yang G, Leftheris K.

J Med Chem. 2003 May 22;46(11):2110-6.

PMID:
12747783
43.

4-1 BB ligand--just another costimulating molecule?

Salih HR, Kiener PA, Nüssler V.

Int J Clin Pharmacol Ther. 2002 Aug;40(8):348-53. Review.

PMID:
12467303
44.
45.

Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences.

Dall'Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, Langermann S.

J Immunol. 2002 Nov 1;169(9):5171-80.

46.

C-3 Amido-indole cannabinoid receptor modulators.

Hynes J Jr, Leftheris K, Wu H, Pandit C, Chen P, Norris DJ, Chen BC, Zhao R, Kiener PA, Chen X, Turk LA, Patil-Koota V, Gillooly KM, Shuster DJ, McIntyre KW.

Bioorg Med Chem Lett. 2002 Sep 2;12(17):2399-402.

PMID:
12161142
47.

Differentiation of promyelocytic leukaemia: alterations in Fas (CD95/Apo-1) and Fas ligand (CD178) expression.

Salih HR, Starling GC, Brandl SF, Pelka-Fleischer R, Haferlach T, Hiddemann W, Kiener PA, Nuessler V.

Br J Haematol. 2002 Apr;117(1):76-85.

PMID:
11918536
48.

Retinoic acid and vitamin E modulate expression and release of CD178 in carcinoma cells: consequences for induction of apoptosis in CD95-sensitive cells.

Salih HR, Starling GC, Knauff M, Llewellyn MB, Davis PM, Pitts WJ, Aruffo A, Kiener PA.

Exp Cell Res. 2001 Nov 1;270(2):248-58.

PMID:
11640888
49.

Cell cycle phase-specific survival of CD95 ligand-challenged Jurkat cells: upregulation of heat-shock response.

Parr TB, Hofman FM, Kiener PA, Stohl W.

Cell Immunol. 2001 Jul 10;211(1):21-9.

PMID:
11585384
50.

Soluble CD137 (4-1BB) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies.

Salih HR, Schmetzer HM, Burke C, Starling GC, Dunn R, Pelka-Fleischer R, Nuessler V, Kiener PA.

J Immunol. 2001 Oct 1;167(7):4059-66.

Supplemental Content

Loading ...
Support Center